These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 38429992)
41. Per- and polyfluoroalkyl substances target and alter human prostate stem-progenitor cells. Hu WY; Lu R; Hu DP; Imir OB; Zuo Q; Moline D; Afradiasbagharani P; Liu L; Lowe S; Birch L; Griend DJV; Madak-Erdogan Z; Prins GS Biochem Pharmacol; 2022 Mar; 197():114902. PubMed ID: 34968493 [TBL] [Abstract][Full Text] [Related]
42. A review of cardiovascular effects and underlying mechanisms of legacy and emerging per- and polyfluoroalkyl substances (PFAS). Wen ZJ; Wei YJ; Zhang YF; Zhang YF Arch Toxicol; 2023 May; 97(5):1195-1245. PubMed ID: 36947184 [TBL] [Abstract][Full Text] [Related]
43. Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress. Liu Y; Conlon DM; Bi X; Slovik KJ; Shi J; Edelstein HI; Millar JS; Javaheri A; Cuchel M; Pashos EE; Iqbal J; Hussain MM; Hegele RA; Yang W; Duncan SA; Rader DJ; Morrisey EE Cell Rep; 2017 May; 19(7):1456-1466. PubMed ID: 28514664 [TBL] [Abstract][Full Text] [Related]
44. Comparative cytotoxicity of seven per- and polyfluoroalkyl substances (PFAS) in six human cell lines. Solan ME; Senthilkumar S; Aquino GV; Bruce ED; Lavado R Toxicology; 2022 Jul; 477():153281. PubMed ID: 35933025 [TBL] [Abstract][Full Text] [Related]
45. High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds. Lu HR; Whittaker R; Price JH; Vega R; Pfeiffer ER; Cerignoli F; Towart R; Gallacher DJ Toxicol Sci; 2015 Dec; 148(2):503-16. PubMed ID: 26358003 [TBL] [Abstract][Full Text] [Related]
46. Interspecies differences in perfluoroalkyl substances (PFAS) toxicokinetics and application to health-based criteria. Pizzurro DM; Seeley M; Kerper LE; Beck BD Regul Toxicol Pharmacol; 2019 Aug; 106():239-250. PubMed ID: 31078680 [TBL] [Abstract][Full Text] [Related]
47. Altered Transcriptome Response in PBMCs of Czech Adults Linked to Multiple PFAS Exposure: B Cell Development as a Target of PFAS Immunotoxicity. Rudzanová B; Thon V; Vespalcová H; Martyniuk CJ; Piler P; Zvonař M; Klánová J; Bláha L; Adamovsky O Environ Sci Technol; 2024 Jan; 58(1):90-98. PubMed ID: 38112183 [TBL] [Abstract][Full Text] [Related]
48. Metabolic Perturbations Associated with an Exposure Mixture of Per- and Polyfluoroalkyl Substances in the Atlanta African American Maternal-Child Cohort. Liang D; Taibl KR; Dunlop AL; Barr DB; Ryan PB; Everson T; Huels A; Tan Y; Panuwet P; Kannan K; Marsit C; Jones DP; Eick SM Environ Sci Technol; 2023 Oct; 57(43):16206-16218. PubMed ID: 37857362 [TBL] [Abstract][Full Text] [Related]
49. A Bayesian Method for Population-wide Cardiotoxicity Hazard and Risk Characterization Using an In Vitro Human Model. Blanchette AD; Burnett SD; Grimm FA; Rusyn I; Chiu WA Toxicol Sci; 2020 Dec; 178(2):391-403. PubMed ID: 33078833 [TBL] [Abstract][Full Text] [Related]
50. Transcriptional effects of binary combinations of PFAS in FaO cells. Bjork JA; Dawson DA; Krogstad JO; Wallace KB Toxicology; 2021 Dec; 464():152997. PubMed ID: 34695511 [TBL] [Abstract][Full Text] [Related]
52. Considering environmental exposures to per- and polyfluoroalkyl substances (PFAS) as risk factors for hypertensive disorders of pregnancy. Erinc A; Davis MB; Padmanabhan V; Langen E; Goodrich JM Environ Res; 2021 Jun; 197():111113. PubMed ID: 33823190 [TBL] [Abstract][Full Text] [Related]
53. Application of a Framework for Grouping and Mixtures Toxicity Assessment of PFAS: A Closer Examination of Dose-Additivity Approaches. Goodrum PE; Anderson JK; Luz AL; Ansell GK Toxicol Sci; 2021 Jan; 179(2):262-278. PubMed ID: 32735321 [TBL] [Abstract][Full Text] [Related]
54. Expanded Systematic Evidence Map for Hundreds of Per- and Polyfluoroalkyl Substances (PFAS) and Comprehensive PFAS Human Health Dashboard. Shirke AV; Radke EG; Lin C; Blain R; Vetter N; Lemeris C; Hartman P; Hubbard H; Angrish M; Arzuaga X; Congleton J; Davis A; Dishaw LV; Jones R; Judson R; Kaiser JP; Kraft A; Lizarraga L; Noyes PD; Patlewicz G; Taylor M; Williams AJ; Thayer KA; Carlson LM Environ Health Perspect; 2024 Feb; 132(2):26001. PubMed ID: 38319881 [TBL] [Abstract][Full Text] [Related]
55. Public Health Risks of PFAS-Related Immunotoxicity Are Real. Bline AP; DeWitt JC; Kwiatkowski CF; Pelch KE; Reade A; Varshavsky JR Curr Environ Health Rep; 2024 Jun; 11(2):118-127. PubMed ID: 38526771 [TBL] [Abstract][Full Text] [Related]
56. Cardiac Toxicity From Ethanol Exposure in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Rampoldi A; Singh M; Wu Q; Duan M; Jha R; Maxwell JT; Bradner JM; Zhang X; Saraf A; Miller GW; Gibson G; Brown LA; Xu C Toxicol Sci; 2019 May; 169(1):280-292. PubMed ID: 31059573 [TBL] [Abstract][Full Text] [Related]
58. Behavior Effects of Structurally Diverse Per- and Polyfluoroalkyl Substances in Zebrafish. Rericha Y; Cao D; Truong L; Simonich M; Field JA; Tanguay RL Chem Res Toxicol; 2021 Jun; 34(6):1409-1416. PubMed ID: 34018735 [TBL] [Abstract][Full Text] [Related]
59. Developing Hazard Rating Calculation Methodologies for Per- and Polyfluoroalkyl Substances. McDougall MRR; Kalinovich I Environ Toxicol Chem; 2021 Mar; 40(3):937-946. PubMed ID: 33410531 [TBL] [Abstract][Full Text] [Related]
60. A Chemical Category-Based Prioritization Approach for Selecting 75 Per- and Polyfluoroalkyl Substances (PFAS) for Tiered Toxicity and Toxicokinetic Testing. Patlewicz G; Richard AM; Williams AJ; Grulke CM; Sams R; Lambert J; Noyes PD; DeVito MJ; Hines RN; Strynar M; Guiseppi-Elie A; Thomas RS Environ Health Perspect; 2019 Jan; 127(1):14501. PubMed ID: 30632786 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]